title: Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria.
abstract: Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU. A randomized study was done in 64 autoimmunity CU patients with positive autologous plasma skin test (APST): 34 patients as treatment and 30 controls. The treatment group was treated with desloratadine and dipyridamole, and the control group was treated with desloratadine only. The efficiency and side-effect were evaluated at the end of treatment. The levels of fragment F(1+2) were measured by enzyme-linked immunosorbent assay in all patients at pre- and post-treatment. The clinical effectiveness rates of treatment and control group were, respectively, 85.20% (21 cured, 8 obvious effectiveness) and 70% (14 cured, 7 obvious effectiveness); they have a significant difference (x = 4.09, P < 0.05). Before treatment, the weals and pruritus in the treatment and control group were, respectively, (1.74 +/- 0.90, 1.79 +/- 0.73) and (1.67 +/- 0.84, 1.73 +/- 0.78). After treatment, the weals and pruritus in treatment and control group were, respectively, (0.38 +/- 0.73, 0.58 +/- 0.89) and (0.67 +/- 0.96, 1.10 +/- 1.12). These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities for treating this disease.
authors: Department of Dermatology, Zhongnan Hospital of Wuhan University, Wuhan, China.
authors: A T
authors: AT
authors: Khalaf
authors: X-M
authors: XM
authors: Liu
authors: W-X
authors: WX
authors: Sheng
authors: J Q
authors: JQ
authors: Tan
authors: A N
authors: AN
authors: Abdalla
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012882:Skin Tests; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D017336:Loratadine; C121345:desloratadine